Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

BIOL

Biolase Inc

Apr 19 • 04:00PM ET

0.1390

Dollar change -0.0095
Percentage change -6.40	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-38.01	Insider Own	4.05%	Shs Outstand	32.52M	Perf Week	-1.97%
Market Cap	4.52M	Forward P/E	-	EPS next Y	-0.11	Insider Trans	0.00%	Shs Float	31.21M	Perf Month	-6.77%
Income	-37.62M	PEG	-	EPS next Q	-0.17	Inst Own	4.58%	Short Float	7.35%	Perf Quarter	-84.30%
Sales	49.16M	P/S	0.09	EPS this Y	98.91%	Inst Trans	1.39%	Short Ratio	0.41	Perf Half Y	-92.01%
Book/sh	-0.07	P/B	-	EPS next Y	65.62%	ROA	-56.30%	Short Interest	2.29M	Perf Year	-99.59%
Cash/sh	0.20	P/C	0.69	EPS next 5Y	20.00%	ROE	-888.93%	52W Range	0.13 - 47.10	Perf YTD	-87.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	59.23%	ROI	-259.26%	52W High	-99.70%	Beta	0.72
Dividend TTM	-	Quick Ratio	0.68	Sales past 5Y	7.86%	Gross Margin	34.02%	52W Low	11.11%	ATR (14)	0.02
Dividend Ex-Date	Jun 24, 2005	Current Ratio	1.26	EPS Y/Y TTM	90.72%	Oper. Margin	-36.48%	RSI (14)	36.89	Volatility	11.39% 14.62%
Employees	157	Debt/Eq	-	Sales Y/Y TTM	1.45%	Profit Margin	-76.52%	Recom	1.00	Target Price	1.63
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	94.24%	Payout	-	Rel Volume	0.24	Prev Close	0.15
Sales Surprise	-0.44%	EPS Surprise	31.12%	Sales Q/Q	-3.99%	Earnings	Mar 21 AMC	Avg Volume	5.62M	Price	0.14
SMA20	-14.99%	SMA50	-20.58%	SMA200	-93.79%	Trades		Volume	1,352,635	Change	-6.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-19-19	Initiated	The Benchmark Company	Speculative Buy	$2
Apr-25-17	Initiated	Singular Research	Buy	$2.50
May-13-14	Downgrade	WallachBeth	Buy → Hold	$4 → $2.50
Nov-12-13	Reiterated	WallachBeth	Buy	$3.50 → $2.75
Aug-08-13	Reiterated	WallachBeth	Buy	$6.50 → $4.50
Jun-17-13	Initiated	WallachBeth	Buy	$6.50
Mar-18-13	Reiterated	Northland Capital	Outperform	$6 → $7
Mar-07-13	Reiterated	Northland Capital	Outperform	$6 → $7
Sep-07-12	Initiated	Northland Securities	Outperform	$4

Mar-23-24 09:53AM	BIOLASE, Inc. (NASDAQ:BIOL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 06:19AM	Q4 2023 BIOLASE Inc Earnings Call (Thomson Reuters StreetEvents) +19.53%
Mar-21-24 08:53PM	BIOL Stock Earnings: Biolase Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:48PM	Biolase: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024 (ACCESSWIRE)
06:30AM	Loading…
Mar-14-24 06:30AM	BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024 (ACCESSWIRE)
Feb-22-24 06:30AM	Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry (ACCESSWIRE) +6.00%
Feb-20-24 06:30AM	Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental' (ACCESSWIRE)
Feb-15-24 02:45PM	BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering (ACCESSWIRE)
Feb-14-24 06:30AM	BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement (ACCESSWIRE) -8.83%
Feb-13-24 09:15AM	BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering (ACCESSWIRE) -63.18%
Jan-29-24 06:30AM	BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024 (PR Newswire) -7.28%
Jan-08-24 04:05PM	BIOLASE ENHANCES EDUCATION OFFERINGS IN 2024 DUE TO INCREASING DEMAND OF DENTAL LASER COURSES THROUGHOUT 2023 (PR Newswire)
Jan-03-24 04:05PM	BIOLASE RECEIVES SECOND TOP WORKPLACES 2023 AWARD (PR Newswire)
Dec-14-23 04:05PM	BIOLASE RECEIVES TOP WORKPLACES 2023 AWARD (PR Newswire) -7.20%
04:05PM	Loading…
Dec-12-23 04:05PM	BIOLASE Successfully Concludes Waterlase iPlus All Tissue Laser Trial (PR Newswire) +6.90%
Dec-06-23 01:46PM	BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Nov-09-23 04:45PM	Biolase: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIES (PR Newswire)
Nov-08-23 06:30AM	Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR Perio Protocol (PR Newswire) -6.65%
Nov-07-23 04:05PM	BIOLASE TO REPORT THIRD QUARTER 2023 RESULTS ON NOVEMBER 9, 2023 (PR Newswire) -5.39%
Oct-18-23 08:00AM	SWK Holdings Highlights Recent Achievements and Provides Portfolio Update (PR Newswire)
Sep-18-23 04:30PM	BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants (PR Newswire)
Sep-13-23 11:16PM	BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants (PR Newswire) -8.43%
Aug-11-23 05:26AM	Q2 2023 BIOLASE Inc Earnings Call (Thomson Reuters StreetEvents) -13.87%
Aug-10-23 04:29PM	Biolase: Q2 Earnings Snapshot (Associated Press Finance) -6.55%
04:05PM	BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEAR (PR Newswire)
Aug-02-23 04:05PM	BIOLASE TO REPORT SECOND QUARTER 2023 RESULTS ON AUGUST 10, 2023 (PR Newswire) -12.65%
Jul-26-23 04:30PM	BIOLASE ANNOUNCES 1-FOR-100 REVERSE STOCK SPLIT (PR Newswire) -7.36%
Jul-17-23 06:30AM	BIOLASE EPIC HYGIENE DENTAL LASER RECEIVES PRESTIGIOUS CELLERANT BEST OF CLASS HYGIENE AWARD (PR Newswire) -5.64%
06:30AM	Loading…
Jun-15-23 06:30AM	BIOLASE Announces Grand Opening of Training Facility to Reach Wider Universe of Dental Practitioners; First-Hand Experience Using Leading Dental Laser Technology Expected to Generate Increased Revenue Opportunities (PR Newswire) +9.12%
Jun-14-23 04:05PM	BIOLASE TO PARTICIPATE IN MAXIM GROUP'S 2023 VIRTUAL HEALTHCARE CONFERENCE HOSTED BY M-VEST ON JUNE 20TH - 22ND (PR Newswire)
06:30AM	BIOLASE INTEGRATES DIODE LASER TECHNOLOGY WITH PET DENTAL SERVICES (PR Newswire)
Jun-05-23 05:30PM	BIOLASE ANNOUNCES DISTRIBUTION OF SERIES I PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCK (PR Newswire) -8.56%
06:30AM	BIOLASE Takes Steps to Improve Operating Efficiency as the Company Pursues Sales and Profitability Goals (PR Newswire)
May-26-23 11:25AM	BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants (PR Newswire)
May-24-23 09:14AM	BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants (PR Newswire) -39.91%
May-11-23 04:36PM	Biolase: Q1 Earnings Snapshot (AP Finance) +26.33%
04:21PM	BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023 (PR Newswire)
May-04-23 04:05PM	BIOLASE TO REPORT FIRST QUARTER 2023 RESULTS ON MAY 11, 2023 (PR Newswire)
Mar-30-23 07:59AM	BIOLASE, Inc. (NASDAQ:BIOL) Q4 2022 Earnings Call Transcript (Insider Monkey) -7.63%
Mar-28-23 04:16PM	Biolase: Q4 Earnings Snapshot (AP Finance)
04:05PM	BIOLASE DELIVERS 24% REVENUE GROWTH IN 2022 AS GO-TO-MARKET STRATEGIES GAIN MOMENTUM; GUIDES FOR AT LEAST 25% REVENUE GROWTH AND PROFITABILITY IN 2023 (PR Newswire)
Mar-14-23 06:30AM	BIOLASE GATHERS KEY OPINION LEADERS AND DENTAL CLINICIANS TO HIGHLIGHT TONGUE-TIE TREATMENT BEST PRACTICES (PR Newswire)
Mar-13-23 06:30AM	BIOLASE TO REPORT FOURTH QUARTER AND FULL YEAR 2022 RESULTS ON MARCH 28, 2023 (PR Newswire)
Mar-06-23 06:30AM	BIOLASE PLANS TO LAUNCH SEASON 2 OF ITS POPULAR PODCAST SERIES (PR Newswire)
Feb-27-23 06:30AM	BIOLASE LAUNCHES E-COMMERCE SITE TO ENHANCE POSITIVE USER EXPERIENCE AND STREAMLINE THE PURCHASING PROCESS TO CREATE GREATER EFFICIENCIES FOR DENTAL PRACTITIONERS (PR Newswire) +5.11%
Feb-23-23 06:30AM	BIOLASE ENTERS THE SKIN RESURFACING MARKET IN THE U.S. WITH THE LAUNCH OF A NEW WATERLASE FRACTIONAL HANDPIECE (PR Newswire)
Feb-21-23 06:30AM	BIOLASE FURTHER ENHANCES MARKET AWARENESS CAMPAIGN WITH THE MUCH ANTICIPATED LAUNCH OF NEW EDUCATION PORTAL (PR Newswire) -8.90%
Feb-16-23 06:00PM	BIOLASE TO PRESENT AT THE THIRD ANNUAL WINTER WONDERLAND BEST IDEAS VIRTUAL INVESTOR CONFERENCE (PR Newswire)
Feb-09-23 04:05PM	BIOLASE RECEIVES SECOND TOP WORKPLACES 2022 AWARD (PR Newswire) -8.70%
Jan-31-23 08:00AM	SWK Holdings Provides Portfolio Update Highlighting Recent Achievements (PR Newswire)
Jan-25-23 06:30AM	BIOLASE REJECTS SONENDO'S "PATENTLY ABSURD" CLAIMS (PR Newswire) -7.74%
Jan-18-23 06:00AM	BIOLASE MAINTAINS POSITIVE MOMENTUM THROUGH YEAR END WITH SOLID FOURTH QUARTER REVENUE GROWTH; SIGNIFICANT MARKET OPPORTUNITY AND INDUSTRY-LEADING PRODUCT SUPPORT EXPECTATION FOR ROBUST REVENUE GROWTH IN 2023 (PR Newswire)
Jan-12-23 04:05PM	BIOLASE RECEIVES TOP WORKPLACES 2022 AWARD (PR Newswire)
Jan-10-23 08:00AM	BIOLASE INC. ANNOUNCES PRICING OF APPROXIMATELY $9.75 MILLION UNDERWRITTEN PUBLIC OFFERING (PR Newswire) -44.95%
Nov-14-22 06:30AM	BIOLASE to Participate in the Benchmark Discovery One-on-One Investor Conference on December 1, 2022 in New York (PR Newswire) +13.41%
Nov-10-22 04:05PM	BIOLASE DELIVERS 26% REVENUE GROWTH YEAR OVER YEAR IN THIRD QUARTER AND RAISES 2022 FULL YEAR REVENUE GUIDANCE (PR Newswire) +11.35%
Oct-27-22 06:30AM	BIOLASE, Inc to Report Third Quarter 2022 Results on November 10, 2022 (PR Newswire)
Oct-18-22 04:05PM	SWK Holdings Provides Portfolio Update Highlighting Recent Achievements (PR Newswire)
Oct-13-22 06:30AM	BIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICER (PR Newswire)
Oct-05-22 06:00AM	BIOLASE LAUNCHES RESEARCH GRANT PORTAL TO ACCELERATE CLINICAL STUDIES ON INNOVATIVE DENTAL LASER TECHNOLOGY (PR Newswire)
Sep-22-22 06:30AM	BIOLASE DOCUSERIES, "TALK DENTAL TO ME" TO BE PRODUCED BY PROVIDENCE FILM GROUP (PR Newswire)
Aug-31-22 06:30AM	BIOLASE ANNOUNCES DEVELOPMENT OF STRATEGIC PLAN TO PARTNER WITH POSTGRADUATE DENTAL SPECIALTY PROGRAMS ACROSS THE U.S. (PR Newswire)
Aug-24-22 04:05PM	BIOLASE TO PARTICIPATE IN THE LAKE STREET 6TH ANNUAL BEST IDEAS GROWTH CONFERENCE SEPTEMBER 14, 2022 (PR Newswire)
Aug-11-22 04:05PM	BIOLASE DELIVERS 34% REVENUE GROWTH YEAR OVER YEAR IN SECOND QUARTER (PR Newswire)
Jul-28-22 06:30AM	BIOLASE, Inc to Report Second Quarter 2022 Results on August 11, 2022 (PR Newswire)
Jul-25-22 06:30AM	BIOLASE EXPANDS INTELLECTUAL PROPERTY PORTFOLIO WITH NEW UNITED STATES AND FOREIGN PATENTS (PR Newswire) -5.32%
Jul-13-22 06:30AM	BIOLASE ANNOUNCES TRAINING INITIATIVE WITH EINSTEIN HEALTHCARE NETWORK'S GENERAL DENTISTRY RESIDENCY PROGRAM (PR Newswire)
Jul-07-22 06:30AM	BIOLASE ANNOUNCES PROMOTIONS OF KEY TEAM MEMBERS (PR Newswire)
Jul-05-22 06:30AM	BIOLASE ANNOUNCES SUPPORT FOR TEAMSMILE PROGRAM (PR Newswire)
Jun-30-22 07:08PM	BIOLASE ENTERS INTO FAVORABLE CREDIT AGREEMENT AMENDMENT (PR Newswire)
Jun-28-22 08:30AM	BIOLASE Announces Pricing of $6.5 Million Registered Direct Offering Priced At-the-Market (PR Newswire) -9.78%
Jun-27-22 06:30AM	BIOLASE ANNOUNCES SUPPORT FOR PROJECT HOME (PR Newswire) +12.80%
Jun-21-22 06:30AM	BIOLASE ANNOUNCES ADVANCING DENTISTRY WEBINARS FOR Q3 2022 (PR Newswire)
Jun-13-22 06:30AM	BIOLASE ANNOUNCES ADVANCING DENTISTRY PODCAST (PR Newswire) -8.91%
Jun-09-22 06:30AM	BIOLASE ANNOUNCES INAUGURAL CLINICAL EXCELLENCE FORUM (PR Newswire)
Jun-06-22 06:30AM	BIOLASE SIGNS LEASE TO EXPAND TRAINING AND EDUCATION INITIATIVES (PR Newswire)
Jun-02-22 06:30AM	BIOLASE TO PRESENT AT LD MICRO INVITATIONAL INVESTOR CONFERENCE ON JUNE 8, 2022 (PR Newswire)
Jun-01-22 06:30AM	BIOLASE CREATES FIRST-OF-ITS-KIND CLINICAL INTEGRATION TEAM (PR Newswire)
May-24-22 06:30AM	BIOLASE CEO SHARES VISION FOR KINDLER, GENTLER DENTISTRY WITH CUSTOMERS AROUND THE WORLD (PR Newswire)
May-16-22 04:05PM	BIOLASE TO PARTICIPATE IN THE SPRING INTO ACTION BEST IDEAS VIRTUAL INVESTOR CONFERENCE MAY 17-20, 2022 (PR Newswire) -5.76%
01:20PM	36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 (ACCESSWIRE)
06:30AM	BIOLASE REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT (PR Newswire)
May-12-22 04:05PM	BIOLASE MAINTAINS GROWTH MOMENTUM AS FIRST QUARTER REVENUE INCREASED 25% YEAR OVER YEAR (PR Newswire) -10.70%
May-09-22 06:30AM	BIOLASE STRENGTHENS ITS BOARD OF DIRECTORS WITH ADDITION OF SEASONED HEALTHCARE EXECUTIVE (PR Newswire) -11.28%
May-04-22 04:05PM	BIOLASE, Inc to Report First Quarter 2022 Results on May 12, 2022 (PR Newswire) +9.84%
Apr-28-22 03:15PM	BIOLASE ANNOUNCES 1-FOR-25 REVERSE STOCK SPLIT (PR Newswire) -34.20%
Mar-23-22 08:30AM	BIOLASE TO PARTICIPATE IN MAXIM GROUP'S 2022 VIRTUAL GROWTH CONFERENCE HOSTED BY M-VEST ON MARCH 28TH - 30TH (PR Newswire)
Mar-17-22 04:05PM	BIOLASE REPORTS CONTINUED GROWTH FOR FOURTH QUARTER AND FULL YEAR 2021 (PR Newswire) +16.63%
Mar-03-22 06:30AM	BIOLASE to Report Fourth Quarter and Full Year 2021 Results on March 17, 2022 (PR Newswire)
Mar-01-22 04:15PM	BIOLASE Announces Distribution of Series G Preferred Stock to Holders of Its Common Stock (PR Newswire)
Feb-10-22 05:10AM	Is BIOLASE (NASDAQ:BIOL) Using Too Much Debt? (Simply Wall St.)
Jan-28-22 10:07AM	36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022 (ACCESSWIRE)
Jan-20-22 08:30AM	BIOLASE Announces Continuation of Exclusive Collaboration with BMW Performance Center West (BMW PCW) and Winner of BMW Sweepstakes (PR Newswire)
Jan-18-22 08:30AM	BIOLASE Announces Continuation of Exclusive Collaboration with BMW Performance Center West (BMW PCW) and Winner of BMW Sweepstakes (PR Newswire)
Jan-10-22 06:30AM	BIOLASE ANNOUNCES POSTIVE PRELIMINARY REVENUE RESULTS FOR 2021 FOURTH QUARTER; ENTERS 2022 WITH SIGNIFICANT MOMENTUM (PR Newswire)
Jan-06-22 09:00AM	BIOLASE and EdgeEndo Announce FDA 510(k) Clearance of New EdgePRO Laser-Assisted Microfluidic Irrigation Device for Endodontists (PR Newswire)
Jan-05-22 08:30AM	BIOLASE TO PRESENT AT THE H.C. WAINWRIGHT BIOCONNECT VIRTUAL INVESTOR CONFERENCE (PR Newswire) -8.43%
Dec-31-21 11:22AM	7 of the Best Penny Stocks Under $3 for 2022 to Buy Now (InvestorPlace)

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1984 and is headquartered in Lake Forest, CA.

Open in Screener

SLNO

Soleno Therapeutics Inc

Apr 19 • 04:00PM ET

37.50

Dollar change +0.35
Percentage change 0.94	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

SLNO Soleno Therapeutics Inc daily Stock Chart

Held by: VTI DWAS VXF LABU SBIO ITOT FHLC HRTS USVM ISCG

Index	-	P/E	-	EPS (ttm)	-2.98	Insider Own	39.22%	Shs Outstand	31.68M	Perf Week	0.97%
Market Cap	1.22B	Forward P/E	-	EPS next Y	-0.75	Insider Trans	-2.44%	Shs Float	19.73M	Perf Month	-14.77%
Income	-38.99M	PEG	-	EPS next Q	-0.37	Inst Own	60.05%	Short Float	13.98%	Perf Quarter	-20.23%
Sales	0.00M	P/S	-	EPS this Y	33.76%	Inst Trans	-0.98%	Short Ratio	9.11	Perf Half Y	58.76%
Book/sh	4.97	P/B	7.54	EPS next Y	51.81%	ROA	-37.64%	Short Interest	2.76M	Perf Year	886.84%
Cash/sh	5.23	P/C	7.17	EPS next 5Y	15.00%	ROE	-46.45%	52W Range	3.16 - 53.82	Perf YTD	-6.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.34%	ROI	-24.73%	52W High	-30.32%	Beta	-1.44
Dividend TTM	-	Quick Ratio	14.89	Sales past 5Y	0.00%	Gross Margin	-	52W Low	1086.71%	ATR (14)	2.00
Dividend Ex-Date	-	Current Ratio	14.89	EPS Y/Y TTM	8.51%	Oper. Margin	0.00%	RSI (14)	36.03	Volatility	3.87% 4.96%
Employees	42	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	64.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	43.56%	Payout	-	Rel Volume	0.63	Prev Close	37.15
Sales Surprise	-	EPS Surprise	-20.75%	Sales Q/Q	-	Earnings	Mar 06 AMC	Avg Volume	302.70K	Price	37.50
SMA20	-7.53%	SMA50	-15.29%	SMA200	36.76%	Trades		Volume	191,106	Change	0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-05-24	Initiated	Piper Sandler	Overweight	$93
Jan-23-24	Initiated	Stifel	Buy	$63
Nov-21-23	Resumed	Guggenheim	Buy	$40
Sep-29-20	Initiated	Guggenheim	Buy	$8
Jan-10-20	Initiated	Craig Hallum	Buy	$8
Dec-23-19	Initiated	Oppenheimer	Outperform	$10
Feb-13-18	Reiterated	Maxim Group	Buy	$8 → $4

Apr-19-24 04:05PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-04-24 01:54AM	CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO) (GuruFocus.com)
01:54AM	Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO) (GuruFocus.com)
Mar-08-24 04:05PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-24 10:53PM	SLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
04:05PM	Loading…
04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-22-24 08:00AM	Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-14-24 08:50AM	Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Feb-05-24 10:10AM	Charter downgraded, Cigna upgraded: Wall Street's top analyst calls (The Fly) +5.91%
Feb-01-24 08:00AM	Soleno Therapeutics to Present at Upcoming February Investor Conferences (GlobeNewswire)
Jan-29-24 04:05PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-26-24 08:50AM	Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going (Zacks)
Jan-24-24 08:00AM	Soleno Therapeutics Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Jan-10-24 08:50AM	Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength (Zacks)
Jan-05-24 08:00AM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06:59PM	Loading…
Dec-21-23 06:59PM	Why Soleno Therapeutics Stock Ticked Higher on Thursday (Motley Fool)
Dec-15-23 09:30AM	Growth Stocks Under $50 for December 2023 (Investopedia)
Dec-14-23 03:44PM	Take Profit: 3 Stocks to Sell That Are Up More Than 200% in 2023 (InvestorPlace)
03:05PM	Insider Sell Alert: CEO Bhatnagar Anish Unloads 93,408 Shares of Soleno Therapeutics Inc (SLNO) (GuruFocus.com)
07:00AM	3 Stock Winners That Are Up 500% or More in 2023 (InvestorPlace)
Dec-01-23 03:06AM	Insider Sell Alert: CFO James Mackaness Sells 8,081 Shares of Soleno Therapeutics Inc (SLNO) (GuruFocus.com)
Nov-27-23 01:02PM	Feeling Lucky? 5 Jackpot Stocks to Buy for 2024. (InvestorPlace)
Nov-20-23 03:06PM	3 Biotech Stocks With Big-Time Breakthrough Potential (InvestorPlace) +8.50%
Nov-10-23 04:05PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-23 08:00AM	Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:00AM	Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome (GlobeNewswire)
Nov-01-23 11:30AM	Top Stocks for November 2023 (Investopedia)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-16-23 04:07PM	The Ten Most-Shorted Stocks Include Huge Market Movers In 2023 (Investor's Business Daily)
08:01AM	Loading…
08:01AM	The 10 Most Shorted Stocks Include 3 Tesla Rivals, But Not TSLA (Investor's Business Daily)
Oct-06-23 06:25PM	Xerox, Mastercraft Boat, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-04-23 06:16PM	Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium (GlobeNewswire)
04:05PM	Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium (GlobeNewswire)
Oct-03-23 08:00AM	Meet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505% (Investor's Business Daily)
Oct-02-23 04:05PM	Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -10.27%
Sep-28-23 09:58AM	Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data (Zacks) +33.48%
08:30AM	Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants (GlobeNewswire)
Sep-27-23 06:08PM	Daily Market Wrap Up: Micron Technology's Mixed Guidance, Morgan Stanley's Dividend Picks, and ... (GuruFocus.com) -22.87%
04:55PM	Why Shares of Soleno Therapeutics Dropped on Wednesday (Motley Fool)
04:01PM	Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants (GlobeNewswire)
03:30PM	Dont Miss the Boom: 3 ETFs Set to Explode Higher (InvestorPlace)
01:28PM	Soleno Therapeutics Stock Dives After Its Meteoric Rise on Positive Study Results (Barrons.com)
07:21AM	Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal (Zacks)
Sep-26-23 04:11PM	Soleno Catapults 505% After Its Pill Controls Hunger In Obesity-Causing Genetic Disease (Investor's Business Daily) +504.97%
12:51PM	Why Shares of Soleno Therapeutics Are Booming on Tuesday (Motley Fool)
12:17PM	Soleno Catapults Almost 400% After Its Pill Controls Hunger In Obesity-Causing Genetic Disease (Investor's Business Daily)
07:30AM	Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome (GlobeNewswire)
Sep-25-23 08:00AM	Soleno Therapeutics to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Aug-18-23 09:02PM	Carlyle Group Inc. Acquires Stake in Soleno Therapeutics Inc. (GuruFocus.com)
Aug-16-23 08:00AM	Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors (GlobeNewswire)
Aug-08-23 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire) +5.77%
Jun-02-23 06:35PM	LL Flooring and Ingevity Stock See Action From Activist Investors (Barrons.com)
May-09-23 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 04:05PM	Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome (GlobeNewswire)
Apr-26-23 06:50AM	Here's Why We're A Bit Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation (Simply Wall St.) -5.95%
Mar-28-23 08:00AM	Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-21-23 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire) +5.94%
Mar-16-23 06:33AM	Soleno Therapeutics, Inc.'s (NASDAQ:SLNO) Shift From Loss To Profit (Simply Wall St.)
Mar-07-23 08:00AM	Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-01-23 04:25PM	7 Top Short-Squeeze Candidates to Watch in February (InvestorPlace)
Jan-26-23 08:00AM	Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome (GlobeNewswire) +7.47%
Jan-13-23 12:00PM	Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +8.18%
Dec-19-22 08:00AM	Soleno Therapeutics Announces Financing Commitment for up to $60 Million (GlobeNewswire) +103.86%
Nov-09-22 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-10-22 11:23AM	Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why (Zacks)
Oct-03-22 08:00AM	Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome (GlobeNewswire)
Sep-30-22 11:47AM	Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA (Zacks)
Sep-29-22 11:42AM	KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study (Zacks) -5.23%
Sep-22-22 10:57AM	Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug (Zacks) -8.08%
Sep-20-22 12:04PM	Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval (Zacks)
Sep-12-22 11:26AM	Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection (Zacks) +5.05%
Sep-07-22 10:02AM	Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds (Zacks)
Sep-06-22 08:00AM	Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-18-22 11:04AM	RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug (Zacks)
Aug-10-22 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-20-22 10:59AM	Soleno Shares Surge On Regulatory Update For Its Prader-Willi Syndrome Hopeful (Benzinga) +5.89%
08:00AM	Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome (GlobeNewswire)
Jul-11-22 04:05PM	Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference (GlobeNewswire) -11.41%
Jul-07-22 09:36AM	Here's Why Assertio Holdings (ASRT) Stock is Up This Year (Zacks) +10.34%
08:39AM	Zacks Industry Outlook Highlights Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics (Zacks)
Jul-06-22 09:32AM	4 Small Stocks to Bet on in an Upbeat Drugs Industry (Zacks)
Jun-14-22 05:56AM	Why Soleno Therapeutics Shares Are Surging Today (Benzinga) +5.93%
Jun-13-22 04:05PM	Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS (GlobeNewswire) -10.66%
Jun-07-22 08:00AM	Soleno Therapeutics Announces Presentations at ENDO 2022 (GlobeNewswire)
May-19-22 04:05PM	Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology (GlobeNewswire)
May-17-22 11:53AM	KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M (Zacks) +7.64%
08:00AM	Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 10:20AM	Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug (Zacks) +6.11%
May-11-22 11:20AM	Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y (Zacks) -6.19%
May-10-22 04:01PM	Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-06-22 11:11AM	Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks) -5.50%
May-05-22 11:26AM	Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y (Zacks) -5.32%
11:07AM	Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates (Zacks)
May-02-22 04:05PM	Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome (GlobeNewswire)
Apr-13-22 03:34PM	High school seniors saw a problem so they started a biotech company (American City Business Journals) +10.64%
Apr-11-22 06:16PM	How Covid stymied a Peninsula company's drug aimed at calming insatiable appetites (American City Business Journals) -6.69%
Apr-01-22 11:49AM	Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering (GlobeNewswire) -5.78%
Mar-31-22 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results (GlobeNewswire)
Mar-29-22 08:30AM	Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering (GlobeNewswire) -22.81%

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Apr 01 '24	Sale	41.34	18,980	784,645	152,790	Apr 03 09:36 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Apr 01 '24	Sale	41.34	5,175	213,937	62,953	Apr 03 09:39 PM
Yen Kristen	SEE REMARKS	Apr 01 '24	Sale	41.34	2,218	91,694	23,422	Apr 03 09:40 PM
Hirano Patricia C	SEE REMARKS	Apr 01 '24	Sale	41.34	2,218	91,694	41,812	Apr 03 09:37 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Jan 25 '24	Sale	48.30	2,527	122,054	171,770	Jan 29 05:42 PM
Hirano Patricia C	SEE REMARKS	Jan 25 '24	Sale	48.30	832	40,186	43,142	Jan 29 05:44 PM
Yen Kristen	SEE REMARKS	Jan 25 '24	Sale	48.30	397	19,175	25,640	Jan 29 05:47 PM
Hirano Patricia C	See Remarks	Dec 14 '23	Sale	36.49	1,359	49,584	19,974	Dec 15 06:00 PM
Yen Kristen	See Remarks	Dec 13 '23	Option Exercise	2.55	17,916	45,644	19,953	Dec 14 07:57 PM
Yen Kristen	See Remarks	Dec 13 '23	Sale	37.76	17,916	676,557	2,037	Dec 14 07:57 PM
Hirano Patricia C	See Remarks	Dec 13 '23	Sale	38.79	4,885	189,513	21,333	Dec 15 06:00 PM
Yen Kristen	See Remarks	Dec 12 '23	Sale	36.95	19,913	735,874	2,037	Dec 14 07:57 PM
Mackaness James H	Chief Financial Officer	Dec 11 '23	Option Exercise	2.60	15,000	38,925	44,610	Dec 13 09:34 PM
Anish Bhatnagar	Chief Executive Officer	Dec 11 '23	Sale	35.67	93,408	3,331,701	24,297	Dec 13 09:34 PM
Mackaness James H	Chief Financial Officer	Dec 11 '23	Sale	36.41	32,482	1,182,828	12,128	Dec 13 09:34 PM
Anish Bhatnagar	Chief Executive Officer	Nov 30 '23	Sale	28.65	27,716	794,116	108,062	Dec 04 08:02 PM
Mackaness James H	Chief Financial Officer	Nov 30 '23	Sale	28.65	4,186	119,937	21,303	Dec 04 08:04 PM
Yen Kristen	See Remarks	Nov 30 '23	Sale	28.65	3,963	113,547	21,950	Dec 04 08:06 PM
Hirano Patricia C	See Remarks	Nov 30 '23	Sale	28.65	3,823	109,536	26,218	Dec 04 08:03 PM
Anish Bhatnagar	Chief Executive Officer	Nov 29 '23	Sale	27.83	27,827	774,535	135,778	Nov 30 09:50 PM
Mackaness James H	Chief Financial Officer	Nov 29 '23	Sale	27.83	4,203	116,986	25,489	Nov 30 09:52 PM
Yen Kristen	See Remarks	Nov 29 '23	Sale	27.83	3,979	110,751	25,913	Nov 30 09:52 PM
Hirano Patricia C	See Remarks	Nov 29 '23	Sale	27.83	3,839	106,855	30,041	Nov 30 09:51 PM
Anish Bhatnagar	Chief Executive Officer	Nov 28 '23	Sale	27.12	25,678	696,514	163,605	Nov 30 09:50 PM
Mackaness James H	Chief Financial Officer	Nov 28 '23	Sale	27.12	3,878	105,190	29,692	Nov 30 09:52 PM
Yen Kristen	See Remarks	Nov 28 '23	Sale	27.12	3,671	99,575	29,892	Nov 30 09:52 PM
Hirano Patricia C	See Remarks	Nov 28 '23	Sale	27.12	3,542	96,076	33,880	Nov 30 09:51 PM
Anish Bhatnagar	Chief Executive Officer	Oct 20 '23	Option Exercise	3.16	9,643	30,500	198,926	Dec 13 09:32 PM
Mackaness James H	Chief Financial Officer	Oct 02 '23	Option Exercise	2.95	8,309	24,497	41,879	Dec 13 09:32 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Sep 28 '23	Buy	20.00	250,000	5,000,000	3,074,542	Sep 28 03:45 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Sep 26 '23	Buy	16.40	616,789	10,113,916	2,824,542	Sep 28 03:45 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Jun 06 '23	Buy	5.93	200	1,186	2,207,753	Jun 06 04:16 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Jun 05 '23	Buy	5.98	78,468	469,239	2,207,553	Jun 06 04:16 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Jun 02 '23	Buy	5.93	64,630	383,256	2,129,085	Jun 06 04:16 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Jun 01 '23	Buy	5.59	7,500	41,925	2,064,455	Jun 01 05:41 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 31 '23	Buy	5.28	10,000	52,800	2,056,955	Jun 01 05:41 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 30 '23	Buy	5.34	17,500	93,450	2,046,955	Jun 01 05:41 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 26 '23	Buy	5.27	22,500	118,575	2,029,455	May 26 05:57 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 25 '23	Buy	5.18	37,500	194,250	2,006,955	May 26 05:57 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 24 '23	Buy	5.48	25,000	137,000	1,969,455	May 26 05:57 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 23 '23	Buy	5.45	27,500	149,875	1,944,455	May 23 06:47 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 22 '23	Buy	5.12	27,300	139,776	1,916,955	May 23 06:47 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 19 '23	Buy	4.62	25,200	116,424	1,889,655	May 23 06:47 PM

Open in Screener

MOTS

Motus GI Holdings, Inc.

Apr 19 • 03:45PM ET

0.0740

Dollar change +0.0040
Percentage change 5.71	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

MOTS Motus GI Holdings, Inc. daily Stock Chart

Index	-	P/E	-	EPS (ttm)	-15.89	Insider Own	1.12%	Shs Outstand	5.21M	Perf Week	-71.87%
Market Cap	0.39M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.97M	Perf Month	-85.77%
Income	-	PEG	-	EPS next Q	-5.48	Inst Own	4.71%	Short Float	0.47%	Perf Quarter	-93.21%
Sales	0.32M	P/S	1.21	EPS this Y	-10.50%	Inst Trans	-	Short Ratio	0.01	Perf Half Y	-98.99%
Book/sh	1.74	P/B	0.04	EPS next Y	-	ROA	-	Short Interest	0.02M	Perf Year	-99.43%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.07 - 23.40	Perf YTD	-94.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-99.68%	Beta	1.52
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	10.45%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	69.35%	Oper. Margin	-	RSI (14)	17.09	Volatility	51.05% 19.58%
Employees	15	Debt/Eq	-	Sales Y/Y TTM	-46.11%	Profit Margin	-	Recom	2.00	Target Price	8.30
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.12	Prev Close	0.07
Sales Surprise	-68.00%	EPS Surprise	-6.92%	Sales Q/Q	-41.30%	Earnings	Mar 18 AMC	Avg Volume	1.67M	Price	0.07
SMA20	-80.11%	SMA50	-86.50%	SMA200	-98.32%	Trades		Volume	196,527	Change	5.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-23	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-30-18	Initiated	Ladenburg Thalmann	Buy	$14.50
Aug-28-18	Initiated	Dougherty & Company	Buy	$8

Mar-18-24 04:05PM	Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-22-24 08:00AM	Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds (GlobeNewswire) -28.18%
Feb-21-24 08:52AM	Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu System to Avoid Clogging in Cleansing the GI Tract (GlobeNewswire) +68.63%
Feb-16-24 04:15PM	Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders (GlobeNewswire)
Jan-30-24 08:00AM	Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation (GlobeNewswire) -25.72%
10:10PM	Loading…
Dec-18-23 10:10PM	Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -16.99%
Nov-13-23 04:05PM	Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-23 08:00AM	Motus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu EVS Gastro (GlobeNewswire) +12.71%
Nov-01-23 08:00AM	Motus GI Announces 1-for-15 Reverse Stock Split (GlobeNewswire) -25.11%
Oct-24-23 08:00AM	Motus GI Receives FDA Clearance to Commercialize Pure-Vu EVS Gastro and Gen 4 Colon (GlobeNewswire) +19.55%
Sep-26-23 08:00AM	Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon (GlobeNewswire)
Sep-14-23 04:05PM	Motus GI Amends Royalty Agreement (GlobeNewswire)
Sep-06-23 05:00PM	Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors (GlobeNewswire)
Aug-24-23 04:05PM	Motus GI to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-14-23 04:01PM	Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
09:00AM	Loading…
Aug-10-23 09:00AM	Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System (GlobeNewswire)
Jul-26-23 05:24AM	Motus Holdings (JSE:MTH) Is Reinvesting At Lower Rates Of Return (Simply Wall St.)
Jul-20-23 08:00AM	Motus GI Announces Purchase Agreement for the Pure-Vu System® from Banner Desert Medical Center (GlobeNewswire)
Jul-13-23 12:00PM	Motus GI Holdings, Inc. (MOTS) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jul-12-23 04:59AM	Lacklustre Performance Is Driving Motus Holdings Limited's (JSE:MTH) Low P/E (Simply Wall St.)
Jun-28-23 02:43AM	If EPS Growth Is Important To You, Motus Holdings (JSE:MTH) Presents An Opportunity (Simply Wall St.)
Jun-14-23 08:00AM	Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 at the Pentax Learning Center (GlobeNewswire)
12:24AM	Boasting A 23% Return On Equity, Is Motus Holdings Limited (JSE:MTH) A Top Quality Stock? (Simply Wall St.)
Jun-07-23 08:30AM	Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer (GlobeNewswire) +9.64%
Jun-05-23 04:42PM	Motus GI Announces Appointment of Ravit Ram as Chief Financial Officer (GlobeNewswire)
May-30-23 08:54AM	Is Now The Time To Look At Buying Motus Holdings Limited (JSE:MTH)? (Simply Wall St.)
May-18-23 08:00AM	Motus GI Announces $3.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.92%
May-17-23 12:16PM	Why Motus GI Stock Is Skyrocketing Today (Benzinga) +38.75%
08:30AM	Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission (GlobeNewswire)
May-16-23 05:18AM	Motus Holdings Limited (JSE:MTH) is a favorite amongst institutional investors who own 51% (Simply Wall St.)
07:00AM	Loading…
May-11-23 07:00AM	Motus GI Announces DDW 2023 Clinical Study Presentation Showing Pure-Vu EVS Drove a 33% Hospital-Wide Improvement in Incomplete Bowel Prep Rate at Minneapolis VA Medical Center (GlobeNewswire)
May-10-23 06:55PM	Motus GI Holdings, Inc. (MOTS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Motus GI Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 02:25AM	Those who invested in Motus Holdings (JSE:MTH) three years ago are up 268% (Simply Wall St.)
Apr-27-23 08:30AM	Angel Medical Systems, Creator of the Guardian, First Implantable Cardiac Alert System, Changes Name to Avertix Medical Inc. and Welcomes New CEO and CFO to Drive Continued Growth and Success (GlobeNewswire)
Apr-13-23 04:05PM	Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones (GlobeNewswire)
Mar-31-23 05:25PM	Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.84%
04:05PM	Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-10-23 11:31AM	Motus GI Holdings Looks For Strategic Alternatives (Benzinga) -7.74%
08:30AM	Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring Plan (GlobeNewswire)
Dec-21-22 08:00AM	Motus GI Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests (GlobeNewswire)
Nov-17-22 06:05AM	Motus GI Holdings Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) -11.54%
Nov-14-22 07:55PM	Motus GI Holdings, Inc. (MOTS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-22 04:05PM	Motus GI to Release Third Quarter Results and Provide a Business Update on November 14 (GlobeNewswire)
Oct-24-22 08:30AM	Motus GI Announces Positive Clinical Data for Pure-Vu EVS in Three Poster Presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting (GlobeNewswire) +23.12%
Oct-21-22 09:12AM	3 Penny Stock Predictions for 2023 (InvestorPlace)
Oct-06-22 12:00PM	Motus GI Holdings, Inc. (MOTS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +38.30%
09:00AM	Motus GI Granted a U.S. Patent for Prepless Colonoscopy Methods Embodied by the Pure-Vu® System (GlobeNewswire)
Sep-29-22 09:00AM	Motus GI Named a Sole Source Supplier with U.S. Department of Veteran Affairs (GlobeNewswire) +8.97%
Aug-11-22 04:05PM	Motus GI Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.12%
08:00AM	Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Aug-04-22 10:00AM	Motus GI Holdings, Inc. (MOTS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -15.00%
Jul-25-22 08:00AM	Motus GI Announces 1-FOR-20 Reverse Stock Split (GlobeNewswire) -14.26%
Jul-21-22 04:05PM	Motus GI to Release Second Quarter Results and Provide a Business Update on August 11 (GlobeNewswire)
May-25-22 08:28AM	Read Why Motus GI Stock Is Surging During Wednesday Premarket (Benzinga) +16.50%
May-24-22 04:05PM	Motus GI Announces Positive Topline Data From EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022 (GlobeNewswire) -5.09%
May-12-22 04:30PM	Edited Transcript of MOTS.OQ earnings conference call or presentation 12-May-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Motus GI Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-05-22 05:35PM	AllScripts Healthcare (MDRX) Q1 Earnings and Revenues Lag Estimates (Zacks)
03:00PM	Will Motus GI Holdings, Inc. (MOTS) Report Negative Earnings Next Week? What You Should Know (Zacks)
May-02-22 08:00AM	Motus GI Announces Upcoming Presentation of Topline Data from the EU Study of the Pure-Vu System at Digestive Disease Week 2022 (GlobeNewswire)
Apr-28-22 08:00AM	Motus GI to Release First Quarter Results and Provide a Business Update on May 12 (GlobeNewswire)
Apr-21-22 08:00AM	Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation (GlobeNewswire)
Apr-08-22 04:29PM	Former Citigroup Executives Seek $100 Million for Crypto Hedge Funds (Bloomberg)
Mar-29-22 06:35PM	Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Motus GI Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-21-22 05:15PM	Strata Skin Sciences, Inc. (SSKN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-15-22 04:05PM	Motus GI to Release Fourth Quarter and Full Year 2021 Results and Provide a Business Update on March 29 (GlobeNewswire)
Mar-02-22 04:05PM	Motus GI to Participate in Two Upcoming Investor Conferences in March 2022 (GlobeNewswire)
Mar-01-22 07:15PM	Senseonics Holdings (SENS) Beats Q4 Earnings and Revenue Estimates (Zacks) +8.11%
Feb-24-22 06:40PM	Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Motus GI Granted 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement (GlobeNewswire)
Feb-14-22 09:14AM	Motus GI Stock Surges On FDA Approval For Next-Gen Pure-Vu EVS System (Benzinga)
06:30AM	Motus GI Receives FDA Clearance to Market the Pure-Vu® EVS System (GlobeNewswire)
Jan-20-22 08:00AM	Motus GI to Host Innovation Day Highlighting the Pure-Vu EVS System (GlobeNewswire)
Dec-16-21 08:30AM	Motus GI Announces U.S. Patent For The Pure-Vu® System's Automatic Self-Purging Features (GlobeNewswire) +5.04%
Dec-07-21 04:30PM	Sidoti December Micro Cap Virtual Conference (ACCESSWIRE) +11.20%
Nov-23-21 08:00AM	Motus GI to Present at Two Upcoming Investor Conferences in December 2021 (GlobeNewswire)
Nov-15-21 12:45PM	Is Motus GI Holdings (NASDAQ:MOTS) A Risky Investment? (Simply Wall St.)
Nov-12-21 08:00AM	Motus GI Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-05-21 03:00PM	Motus GI Holdings, Inc. (MOTS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
12:00PM	Sidoti Microcap Virtual Conference (ACCESSWIRE)
Oct-28-21 04:05PM	Motus GI to Release Third Quarter Results and Provide a Business Update on November 12 (GlobeNewswire)
Oct-26-21 08:00AM	Motus GI Announces Presentation of Results from Independent Study of Pure-Vu System in IBP Patients at the 2021 ACG Annual Scientific Meeting (GlobeNewswire) +18.17%
Sep-28-21 08:00AM	Motus GI Announces the Passing of Independent Director Dr. Sam Nussbaum (GlobeNewswire)
Sep-13-21 08:00AM	Motus GI to Present at the Oppenheimer & Co. Inc. Fall Healthcare Summit (GlobeNewswire)
Sep-08-21 08:05AM	Motus GI Announces Enrollment of Patients at Second Site in the European Union Outpatient Study of the Pure-Vu® System (GlobeNewswire)
Sep-07-21 08:00AM	Motus GI to Participate in Two Upcoming Investor Conferences in September 2021 (GlobeNewswire)
Aug-12-21 07:05PM	Motus GI Holdings, Inc. (MOTS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Motus GI Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-21 04:05PM	Motus GI to Release Second Quarter Results and Provide a Business Update on August 12 (GlobeNewswire)
Jul-21-21 08:00AM	Motus GI Secures Expanded $12M Credit Financing to Support Growth Strategy (GlobeNewswire)
Jun-29-21 04:05PM	Motus GI to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
08:04AM	Is Motus GI Holdings, Inc. (MOTS) A Good Stock To Buy? (Insider Monkey)
Jun-23-21 04:05PM	Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee (GlobeNewswire)
Jun-16-21 08:00AM	Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation (GlobeNewswire)
Jun-03-21 08:00AM	Motus GI Announces Publication of Pure-Vu® System Clinical Data in Peer-Reviewed Journal BMC Gastroenterology (GlobeNewswire)
May-25-21 08:05AM	Motus GIs Pure-Vu System® Adopted by Sinai Hospital of Baltimore (GlobeNewswire)
May-17-21 09:14AM	Is Motus GI Holdings (NASDAQ:MOTS) Using Debt Sensibly? (Simply Wall St.) +5.75%

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in 2008 and is headquartered in Fort Lauderdale, FL.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

BIOL

Biolase Inc

SLNO

Soleno Therapeutics Inc

MOTS

Motus GI Holdings, Inc.

Upgrade your FINVIZ experience